Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Safina Ali, … , Maureen J. Charron, Daniel J. Drucker
Safina Ali, … , Maureen J. Charron, Daniel J. Drucker
Published April 11, 2011
Citation Information: J Clin Invest. 2011;121(5):1917-1929. https://doi.org/10.1172/JCI43615.
View: Text | PDF
Research Article Metabolism

Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis

  • Text
  • PDF
Abstract

Disordered glucagon secretion contributes to the symptoms of diabetes, and reduced glucagon action is known to improve glucose homeostasis. In mice, genetic deletion of the glucagon receptor (Gcgr) results in increased levels of the insulinotropic hormone glucagon-like peptide 1 (GLP-1), which may contribute to the alterations in glucose homeostasis observed in Gcgr–/– mice. Here, we assessed the contribution of GLP-1 receptor (GLP-1R) signaling to the phenotype of Gcgr–/– mice by generating Gcgr–/–Glp1r–/– mice. Although insulin sensitivity was similar in all genotypes, fasting glucose was increased in Gcgr–/–Glp1r–/– mice. Elimination of the Glp1r normalized gastric emptying and impaired intraperitoneal glucose tolerance in Gcgr–/– mice. Unexpectedly, deletion of Glp1r in Gcgr–/– mice did not alter the improved oral glucose tolerance and increased insulin secretion characteristic of that genotype. Although Gcgr–/–Glp1r–/– islets exhibited increased sensitivity to the incretin glucose-dependent insulinotropic polypeptide (GIP), mice lacking both Glp1r and the GIP receptor (Gipr) maintained preservation of the enteroinsular axis following reduction of Gcgr signaling. Moreover, Gcgr–/–Glp1r–/– islets expressed increased levels of the cholecystokinin A receptor (Cckar) and G protein–coupled receptor 119 (Gpr119) mRNA transcripts, and Gcgr–/–Glp1r–/– mice exhibited increased sensitivity to exogenous CCK and the GPR119 agonist AR231453. Our data reveal extensive functional plasticity in the enteroinsular axis via induction of compensatory mechanisms that control nutrient-dependent regulation of insulin secretion.

Authors

Safina Ali, Benjamin J. Lamont, Maureen J. Charron, Daniel J. Drucker

×

Figure 7

Enteroinsular axis is maintained in DIRKO mice treated with Gcgr ASOs.

Options: View larger image (or click on image) Download as PowerPoint
Enteroinsular axis is maintained in DIRKO mice treated with Gcgr ASOs.
(...
(A) mRNA expression of Gcgr in the liver (n = 3 per group) following treatment with 6 injections of 25 mg/kg Gcgr ASOs. (B) Total plasma GLP-1 levels following 2, 4, or 6 injections of 25 mg/kg saline or Gcgr ASOs (n = 5 per group). (C and D) An i.p. glucose challenge was performed on 13- to 14-week-old male (C) WT mice and (D) DIRKO mice that had been treated with 3 injections of vehicle or 25 mg/kg Gcgr ASOs (n = 5 per group). (E and F) An OGTT was performed on 15- to 16-week-old (E) WT mice and (F) DIRKO mice that had been treated with 4 injections of vehicle or 25 mg/kg Gcgr ASOs (n = 5 per group). Insets depict plasma insulin levels at 0 and 15 minutes following glucose challenge for saline- or Gcgr ASO–treated mice (n = 5 per treatment group). Values are expressed as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, vehicle- versus Gcgr ASO–treated WT or DIRKO mice.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts